Merck Investors Rip Fee Requests In $688M Vytorin Deal

Law360, New York (August 6, 2013, 3:08 PM EDT) -- Investors in two class actions alleging Merck & Co. and its Schering-Plough subsidiary hid test results for their anti-cholesterol drug Vytorin challenged a proposed $688 million settlement of the cases on Monday, saying attorneys' fee requests in the actions were too high.

Class counsel in the Schering-Plough action have asked for $80 million, while counsel in the Merck class action have asked for $60 million. The objectors urged the New Jersey federal court to trim the amounts based on the actual time and effort that counsel...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.